• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Cereno Scientific

4,62 SEK

+4,86 %

Mindre end 1K følgere

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+4,86 %
-16,83 %
-23,00 %
-33,96 %
-44,62 %
-57,02 %
+901,30 %
+32,26 %
-23,21 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Læs mere
Markedsværdi
1,44 mia. SEK
Aktieomsætning
4,4 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
EPS og udbytte
Finanskalender
Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
17.6
2026

Generalforsamling '26

26.8
2026

Delårsrapport Q2'26

4.11
2026

Delårsrapport Q3'26

Pressemeddelelse3.6.2026, 05.45

Cereno Scientific to present at BIO International Convention 2026 and advance global partnering discussions

Cereno Scientific
Eksterne analyser27.5.2026, 06.49

Cereno Scientific: Preclinical development for CS585 - Edison

Cereno Scientific has announced that its third asset, CS585 (a potent and selective agonist of the prostacyclin receptor), will be tested in preclinical disease model studies relating to antiphospholipid syndrome (APS), a rare autoimmune disease associated...

Cereno Scientific
Selskabsmeddelelse27.5.2026, 06.00

Cereno Scientific Publishes Interim Report for Q1 2026

Cereno Scientific

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse26.5.2026, 05.45

Cereno Scientific Confirms First Volunteer Dosed in CS014 PK-bridging Study Supporting Phase II Development in PH-ILD

Cereno Scientific
Selskabsmeddelelse22.5.2026, 17.24

Cereno Scientific publishes Annual Report for 2025

Cereno Scientific
Pressemeddelelse21.5.2026, 05.45

Cereno Scientific to Initiate Preclinical Evaluation of CS585 in Rare Disease Antiphospholipid Syndrome (APS) Progressing toward Clinical Phase

Cereno Scientific
Selskabsmeddelelse15.5.2026, 12.30

Cereno Scientific give notice to attend the Annual General Meeting 2026

Cereno Scientific
Pressemeddelelse11.5.2026, 05.30

Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension

Cereno Scientific
Pressemeddelelse10.4.2026, 06.45

Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026

Cereno Scientific
Pressemeddelelse4.4.2026, 06.00

Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH

Cereno Scientific
Selskabsmeddelelse31.3.2026, 05.30

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program

Cereno Scientific
Pressemeddelelse27.3.2026, 10.09

Cereno Scientific: Stifel Initiates Coverage with Buy Rating and Price Target of SEK 20

Cereno Scientific
Eksterne analyser24.3.2026, 12.28

Cereno Scientific: Inflection points coming into view - Edison

Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226, we anticipate a step-up in clinical activity and partnering...

Cereno Scientific
Pressemeddelelse17.3.2026, 11.20

Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD

Cereno Scientific
Pressemeddelelse12.3.2026, 06.45

Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon

Cereno Scientific
Selskabsmeddelelse27.2.2026, 06.45

Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025)

Cereno Scientific
Eksterne analyser20.2.2026, 10.31

Cereno Scientific: CMD reaffirms shifting focus to clinical delivery - Edison

Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by key opinion leader (KOL) and patient perspectives, ...

Cereno Scientific
Pressemeddelelse4.2.2026, 09.00

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific
Pressemeddelelse3.2.2026, 06.45

Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026

Cereno Scientific
Pressemeddelelse2.2.2026, 13.00

Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026

Cereno Scientific